Carrier for nucleic acid and method for administering nucleic acid

Plant-derived vesicles form a complex with nucleic acids, addressing the lack of effective DDS for nucleic acid delivery by ensuring retention and introduction into cells, enhancing medical applications like gene therapy.

JP7587843B2Active Publication Date: 2024-11-21TOKYO MEDICAL UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021530681
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-07-05
Filing Date
2020-07-03
Publication Date
2024-11-21
Estimated Expiration
2040-07-03

AI Technical Summary

Technical Problem

The development of an effective drug delivery system (DDS) for nucleic acid reagents such as siRNA, shRNA, and microRNA to introduce them into cells with good reproducibility has not been established.

Method used

A carrier system utilizing vesicles derived from plant fruits, specifically from Malpighiaceae and Rutaceae plants, is used to form a complex with nucleic acids, allowing for their retention and introduction into cells.

Benefits of technology

The plant-derived vesicles effectively retain and introduce nucleic acids into cells, providing a useful DDS for medical applications like gene therapy by preventing degradation and ensuring efficient delivery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587843000001
    Figure 0007587843000001
  • Figure 0007587843000002
    Figure 0007587843000002
  • Figure 0007587843000003
    Figure 0007587843000003
Patent Text Reader

Abstract

Provided is a novel carrier for introducing a nucleic acid, e.g., siRNA, into a cell. The nucleic acid carrier according to the present invention is characterized by comprising a vesicle from a plant of the Malpighiaceae family, and preferably a vesicle derived from acerola. The method according to the present invention for administering a nucleic acid is characterized by comprising a step for forming a complex between a nucleic acid and the nucleic acid carrier according to the present invention, and a step for administering the complex.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to carriers for nucleic acids and methods for administering nucleic acids. [Background technology]

[0002] In recent years, applications of nucleic acid reagents such as siRNA, short hairpin RNA (shRNA), and microRNA (miRNA) that suppress gene expression have been attempted in the medical field. However, drug delivery systems (DDS) for introducing the nucleic acid reagents into cells are still under development, and a carrier that can hold nucleic acids and introduce nucleic acids into cells with good reproducibility has not yet been established. Summary of the Invention [Problem to be solved by the invention]

[0003] Therefore, an object of the present invention is to provide a new carrier for introducing a nucleic acid such as siRNA into a cell. [Means for solving the problem]

[0004] In order to achieve the above object, the nucleic acid carrier of the present invention is characterized in that it contains vesicles from plant fruits.

[0005] The delivery-type nucleic acid reagent of the present invention comprises the nucleic acid carrier of the present invention and a nucleic acid, and is characterized in that the nucleic acid carrier and the nucleic acid form a complex.

[0006] The method for producing a delivery-type nucleic acid reagent of the present invention is characterized by including a step of forming a complex between the nucleic acid carrier and the nucleic acid by causing the nucleic acid carrier of the present invention and the nucleic acid to coexist in a solvent.

[0007] The method for administering a nucleic acid of the present invention is characterized by comprising the steps of forming a complex between the carrier for nucleic acid of the present invention and a nucleic acid, and administering the complex. Effect of the Invention

[0008] According to the nucleic acid carrier of the present invention, for example, a nucleic acid can be easily retained and the retained nucleic acid can be introduced into a cell. Therefore, the present invention can be said to be very useful as a DDS in the medical field, for example, in gene therapy. [Brief description of the drawings]

[0009] [Figure 1] FIG. 1 is a graph showing the particle size distribution of acerola-derived vesicles in Example 1. [Diagram 2] FIG. 2 is a graph showing the expression of the nucleic acid reagent in Example 1. [Diagram 3] FIG. 3 is a photograph showing the uptake of a nucleic acid reagent using the vesicles in Example 1. [Figure 4] FIG. 4 is a graph showing the uptake of a nucleic acid reagent into cells SiHa using the vesicles in Example 1 and the inhibition of target expression. [Diagram 5] FIG. 5 is a graph showing the uptake of a nucleic acid reagent into NHDF cells using the vesicles in Example 1 and the inhibition of target expression. [Figure 6] FIG. 6 is a graph showing the results of confirming the formation of a complex between vesicles and a nucleic acid reagent by comparing the amount of amplification of the nucleic acid reagent in Example 2. [Figure 7] FIG. 7 is a graph showing the results of confirming the influence of heat shock and ice-cooling on complex formation depending on the amount of amplification of the nucleic acid reagent in Example 2. [Figure 8] FIG. 8 is a graph showing the results of confirming the influence of incubation conditions on complex formation based on the amount of amplification of the nucleic acid reagent in Example 2. [Figure 9] FIG. 9 is a graph showing the results of confirming the correlation between complex formation and the amount of vesicles added, based on the amount of amplification of the nucleic acid reagent, in Example 2. [Figure 10] FIG. 10 is a graph showing the results of confirming the inhibition of decomposition of a nucleic acid reagent by vesicles based on the amount of amplification of the nucleic acid reagent in Example 3. [Figure 11]FIG. 11 is a graph showing the introduction of a nucleic acid reagent into cells through complex formation in Example 4. [Figure 12] FIG. 12 is a schematic diagram showing the introduction of a nucleic acid reagent into a mouse by complex formation in Example 5. [Figure 13] FIG. 13 is a graph showing the amount of amplified nucleic acid reagent in each organ when the nucleic acid reagent was introduced into a mouse by forming a complex in Example 5. [Figure 14] FIG. 14 is a graph confirming the function of the nucleic acid reagent introduced into mice as a complex in Example 5. [Figure 15] FIG. 15 is a graph showing the results of confirming the inhibition of decomposition of a nucleic acid reagent by vesicles based on the amount of amplification of the nucleic acid reagent in Example 6. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] Terms used in this specification can be used in the same manner as commonly used in the art unless otherwise specified.

[0011] (1) Nucleic acid carrier The nucleic acid carrier of the present invention is characterized by containing vesicles from plant fruits as described above. The present inventors found that vesicles from plant fruits hold nucleic acids, that a complex of the nucleic acid and the vesicles is taken up into cells, and that the held nucleic acid functions within the cells, leading to the establishment of the present invention. The present invention is characterized by containing the vesicles, and other configurations and conditions are not particularly limited.

[0012] The plant from which the fruit of the plant is derived is not particularly limited, and examples thereof include plants of the Malpighiaceae family and plants of the Rutaceae family.

[0013] The type of the Malpighiaceae plant is not particularly limited, and examples thereof include the genus Malpighia, and specifically, examples thereof include Acerola species (Malpighia sp.), and preferably Acerola such as M. emarginata DC., M. glabra, and M. punicifolia.

[0014] The type of Rutaceae plant is not particularly limited, and examples thereof include the genus Citrus, specifically, grapefruit species (Citrus × paradisi, English name: grapefruit), lemon species (C. limon, English name: lemon), and the like.

[0015] The vesicles can be obtained from the fruit of the plant. The fruit may be, for example, ripe, unripe, or a mixture thereof. The vesicles are preferably, for example, a vesicle fraction recovered from the juice of the fruit, as described below.

[0016] The vesicles can be prepared, for example, by extraction from the fruit of the plant. The preparation method is not particularly limited, and can be obtained, for example, by crushing the fruit, preparing the crushed product or a suspension of the crushed product, and fractionating the vesicles by ultrafiltration, ultracentrifugation, concentration gradient method, separation method using a micro liquid system, or the like. For the preparation method, for example, a commercially available kit can be used, and ExoEasy Maxi Kit (trade name, QIAGEN), ExoQuick (trade name, System Bioscience), Total Exosome Isolation reagent (trade name, Invitrogen), etc. can be used. For example, the vesicles can be obtained by subjecting the juice obtained by squeezing the fruit to various separation methods as described above. The juice can be, for example, the juice of ripe fruit, the juice of unripe fruit, or the juice of ripe or unripe frozen fruit.

[0017] The nucleic acid carrier of the present invention can be, for example, a vesicle fraction containing a plurality of vesicles. The size of the vesicles is not particularly limited, and the particle size can be, for example, 30 to 400 nm, 80 to 300 nm, 150 to 300 nm, 100 to 200 nm, or 80 to 200 nm. The vesicles are also called, for example, microvesicles or nanovesicles. The vesicle fraction containing a plurality of vesicles has a particle size peak of, for example, 30 to 400 nm, 80 to 300 nm, 150 to 300 nm, 100 to 200 nm, or 80 to 200 nm, when expressed in terms of particle size distribution. In addition, in the particle size distribution, when the total vesicles are taken as 100%, the lower limit of the proportion of vesicles at the peak (e.g., 200±20 nm) is, for example, 30% or more, 50% or more, or 80% or more, and the upper limit is, for example, 100%, 80% or less, or 70% or less. The vesicle fraction is, for example, a fraction extracted from the fruit juice so as to have the particle size and particle size distribution. When the vesicle fraction is used as the nucleic acid carrier of the present invention, for example, a fraction extracted from the plant fruit by an extraction method so as to have the particle size and particle size distribution can be used, and it may be in a state containing other components derived from the fruit juice.

[0018] The method for measuring the particle size of vesicles is not particularly limited, and for example, a method such as nanoparticle tracking analysis can be adopted, and for example, a commercially available device (instrument name NanoSight, qNANO) can be used. The vesicles may be, for example, extracellular vesicles or intracellular vesicles. For example, the vesicles may be exosome-like vesicles (same size as human-derived exosomes). Vesicles of the same size as human-derived exosomes are, for example, vesicles obtained by the same isolation method as human-derived exosomes.

[0019] The nucleic acid carrier of the present invention can form a complex with a nucleic acid. Specifically, the vesicle can form a complex with the nucleic acid. The nucleic acid can be delivered by forming a complex between the nucleic acid and the nucleic acid carrier, and the complex is hereinafter also referred to as a delivery type nucleic acid reagent. The form of the complex is not particularly limited, and may be, for example, a form in which the nucleic acid is encapsulated inside the vesicle, or a form in which the nucleic acid is supported on the outer wall of the vesicle. The method of forming a complex between the vesicle and the nucleic acid is not particularly limited, and may be, for example, simply by allowing the vesicle and the nucleic acid to coexist in a solvent, or a general method for introducing nucleic acid into cells can be used. In the former case, for example, the vesicle and the nucleic acid can be allowed to coexist in a solvent and incubated to form a complex between the vesicle and the nucleic acid. The incubation temperature is not particularly limited, and may be, for example, in the room temperature range (e.g., 30±10°C) or in a lower temperature range (e.g., more than 0°C and less than 20°C), and is preferably in the low temperature range (e.g., 4±5°C) since it is possible to prevent the decomposition of the nucleic acid before the complex formation when RNase is mixed, and more preferably under ice-cooled conditions (e.g., 1 to 6°C). The incubation time is not particularly limited, and the lower limit is, for example, 5 minutes or more, 15 minutes or more, and the upper limit is not particularly limited, and the complex formation plateau can be reached by incubation for about 30 minutes. The solvent is not particularly limited, and liquids such as water, physiological saline, and buffer solutions such as PBS can be used. In the latter case, for example, electroporation method, lipofection method, etc. can be used.

[0020] So far, as a DDS for nucleic acids, for example, a method of introducing nucleic acids into a carrier by electroporation or the like has been reported, but an effective means has not been clarified in terms of reproducibility, etc. For such reasons, for example, in a method of using animal-derived exosomes for DDS, a method of modifying exosome-producing cells themselves has been adopted. In contrast, the nucleic acid carrier of the present invention can very easily hold the nucleic acid that is the subject of DDS in the vesicles, since the vesicles of the plant fruit can form a complex between the vesicles and the nucleic acid simply by coexisting the nucleic acid in the solvent, as described above. Furthermore, according to the nucleic acid carrier of the present invention, for example, the nucleic acid can be introduced into the cell from outside the cell by endocytosis of the vesicles by forming a complex between the nucleic acid and the vesicles.

[0021] As described above, the formation of the complex may be achieved by, for example, simply allowing the nucleic acid and the vesicles to coexist in the solvent, and a conventional transfection method or the like may be omitted in order to allow the vesicles to carry the nucleic acid. Examples of the transfection method include a heat shock method in which calcium chloride is added. The heat shock method is, for example, a method in which the temperature is changed in the presence of a carrier (for example, a cell) carrying the nucleic acid and the nucleic acid, and the temperature is then incubated for a predetermined period of time and returned to the original temperature, thereby performing a heat treatment. The temperature change is, for example, a change from a relatively low temperature (treatment temperature before the change) to a relatively high temperature (treatment temperature after the change), and it is preferable to return to a relatively low temperature after incubation at a relatively high temperature. The range of temperature change (temperature difference due to the change) is, for example, 5 to 45°C, and the treatment temperature before the change is, for example, a low temperature, specifically, 1 to 10°C, and the treatment temperature after the change is, for example, a high temperature, specifically, 40 to 46°C.

[0022] Furthermore, the nucleic acid carrier of the present invention can prevent the decomposition of nucleic acid caused by RNase, acid, alkali, etc., for example, by forming a complex with nucleic acid. Therefore, the nucleic acid carrier of the present invention can also be said to be an agent for preventing the decomposition of nucleic acid.

[0023] The nucleic acid is, for example, a nucleic acid reagent for expression inhibition. The mechanism of expression inhibition of the nucleic acid reagent is not particularly limited, and may be, for example, gene expression inhibition or protein expression inhibition, and specifically includes inhibition of transcription from genes, inhibition of translation into proteins, and degradation of transcripts. The type of the nucleic acid reagent is not limited at all, and may be, for example, siRNA, antisense, shRNA, miRNA, miRNA mimic (see, for example, WO2015 / 099122), etc.

[0024] In forming the complex, the ratio of the amount of the vesicles to the amount of the nucleic acid is not particularly limited, and may be, for example, 5×10 vesicles per pmol of the nucleic acid. 4 ~8×10 4 Particles, 2×10 5 ~5×10 5 Particles, 2×10 6 ~5×10 6 particles.

[0025] The site to which the nucleic acid carrier of the present invention can deliver the nucleic acid is not particularly limited, and examples thereof include the liver, intestine (rectum, intestinal tract, stomach, etc.), brain, and spleen.

[0026] The nucleic acid carrier of the present invention is useful, for example, as a pharmaceutical, diagnostic agent, agricultural chemical, and a research tool in agriculture, medicine, life science, and the like.

[0027] (2) Delivery-type nucleic acid reagent of the present invention and its manufacturing method As described above, the delivery type nucleic acid reagent of the present invention is characterized in that it contains the nucleic acid carrier of the present invention and the nucleic acid, and the nucleic acid carrier and the nucleic acid form a complex. Specifically, the vesicle in the nucleic acid carrier of the present invention and the nucleic acid form a complex. The description of (1) above can be used for the delivery type nucleic acid reagent of the present invention (the complex).

[0028] As described above, the method for producing the delivery-type nucleic acid reagent of the present invention includes a step of forming a complex between the nucleic acid carrier and the nucleic acid by causing the nucleic acid carrier of the present invention and the nucleic acid to coexist in the solvent. The description of (1) above can be used for the production method of the present invention.

[0029] (3) Method of administering nucleic acid As described above, the method for administering a nucleic acid of the present invention is characterized by comprising the steps of forming a complex between the carrier for nucleic acid of the present invention and a nucleic acid, and administering the complex. The present invention is characterized by using the carrier for nucleic acid of the present invention, and other steps and conditions, etc. are not limited in any way.

[0030] The method for forming the complex is not particularly limited, and for example, as described above, the vesicle and the nucleic acid may be simply allowed to coexist, or an electroporation method, etc. may be used. In the present invention, the former is preferred because it allows the complex to be easily formed.

[0031] In the step of forming the complex, the ratio of the vesicles to the nucleic acid is not particularly limited, and for example, 8 Each nucleic acid contains 50 to 100 pmol.

[0032] The form of administration is not particularly limited, and may be, for example, in vivo or in vitro. When the administration is in vitro, the subject of administration may be, for example, a cell, tissue, or organ. When the administration is in vivo, the method of administration is not particularly limited, and may be, for example, oral administration or parenteral administration. The parenteral administration may be, for example, intravenous, intraarterial, intramuscular, subcutaneous, intraperitoneal, or local administration.

[0033] The subject of administration can be, for example, a human or a non-human animal, and the non-human animal is not particularly limited, and can be, for example, a mouse, a rat, a rabbit, a dog, a camel, or a cow.

[0034] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these. EXAMPLES

[0035] Example 1 The function of acerola-derived vesicles as a nucleic acid carrier was confirmed. Kits, reagents, and equipment were used according to their instruction manuals. Unless otherwise specified, the same conditions were used for each treatment in the following examples.

[0036] (1) Preparation of vesicles 8 mL of juice from ripe Okinawan acerola fruit was filtered using a membrane filter with a pore size of 0.45 μm (trade name Durapore™ PVDF Membrane Filter, Millipore). 8 mL of the obtained filtrate was subjected to a kit (trade name exoEasy Maxi Kit, QIAGEN), and vesicles were separated (isolated) by elution using 400 μL of Buffer XE from the kit, and the eluted fraction was subjected to ultracentrifugation (100,000×g, 49,000 rpm, 70 minutes, 4° C.) to recover a pellet of vesicles. The pellet was suspended in 50 μL of PBS to obtain a vesicle fraction. The vesicle fraction was subjected to a nanoparticle analysis system (trade name NanoSight, Malvern) to confirm the particle size distribution of vesicles contained in the vesicle fraction.

[0037] The particle size distribution results are shown in the graph of Figure 1. In Figure 1, the vertical axis indicates particle concentration (particles / mL) and the horizontal axis indicates particle diameter (nm). As shown in Figure 1, the vesicle concentration of the vesicle fraction was 2.2 x 10 8 The mean particle size was 208 nm, the mode was 155 nm, and the SD was 108 nm.

[0038] (2) Complex formation The formation of a complex between the nucleic acid reagent and the vesicles was indirectly confirmed.

[0039] The nucleic acid reagent used was a miRNA mimic targeting MMP2 (trade name Ambion (trademark) miR-340 mimic, Thermo Fisher Scientific). 200 pmol of the miR-340 mimic was mixed with 1 mL of the vesicle fraction, calcium chloride was added to a concentration of 0.1 mol / L, and the mixture was left on ice for 30 minutes, then left at 42°C for 1 minute, and then left on ice for 5 minutes again to perform a heat shock method. The mixture was then ultracentrifuged to recover the precipitated fraction. The ultracentrifugation was performed under conditions where the vesicles precipitated and the miRNA mimic did not precipitate by itself (100,000×g, 49,000 rpm, 70 minutes, 4°C, the same below). A system in which RNase was added to the precipitate fraction at 5 μg / mL and a system in which RNase was not added were prepared, and after treatment at 37° C. for 1 hour, RNA was extracted using miRNeasy mini kit (trade name, Qiagen) and miR-340 mimic was measured by qRT-PCR. This system is called b. The qRT-PCR was performed by adding spike miRNA (ath-miR-159) to a specified amount (0.1 μmol / L) as a spike control, and the spike miRNA was also measured in the same manner (hereinafter the same).

[0040] The miR-340 mimic was not added, and calcium chloride was added to 1 mL of the vesicle fraction to a concentration of 0.1 mol / L. The mixture was left on ice for 30 minutes, then left at 42°C for 1 minute, and then left on ice for 5 minutes again, in a heat shock method. The mixture was then ultracentrifuged to recover the precipitated fraction, and a system with and without RNase was prepared, which was treated in the same manner as in the system b, and measurements were performed. This system is called system a.

[0041] 200 pmol of the miR-340 mimic was mixed with 1 mL of the vesicle fraction, and the mixture was left on ice for 30 minutes, after which the precipitate fraction was collected by ultracentrifugation. For the precipitate fraction, a system with and without RNase was prepared, and the measurement was performed by treating the system in the same manner as in system b. This system was not added with calcium chloride, and was not subjected to heat shock treatment. This system is referred to as system c.

[0042] 200 pmol of the miR-340 mimic was mixed with 1 mL of PBS and left to stand on ice for 30 minutes. After that, a system with and without RNase was prepared for this mixture, and the measurement was performed by treating it in the same manner as in the system b. This system was not added with the vesicle fraction, not added with calcium chloride, not subjected to heat shock, and not subjected to ultracentrifugation. This system is called system d.

[0043] 200 pmol of the miR-340 mimic was mixed with 1 mL of PBS, left on ice for 30 minutes, and then ultracentrifuged to remove the liquid fraction. For the remaining material, a system with and without RNase was prepared, and the measurement was performed by treating the system in the same manner as the system b. This system was not added with the vesicle fraction, not added with calcium chloride, and not subjected to heat shock treatment. This system is called system e.

[0044] These results are shown in Figure 2. Figure 2 is a graph showing the amount of amplification (detection amount) of miR-340 mimic. The Y axis is the relative value of the amount of amplification of miR-340 mimic. Specifically, for each system, the amount of amplification of miR-340 mimic was normalized by the amount of amplification (detection amount) of the spike control ath-miR-159, and the normalized value of system d (RNase not added) was set to 1, and the values ​​were expressed as relative values. In Figure 2, a to e are the results of systems a to e, respectively, with the left bar showing the results of the system not treated with RNase (RNase-) and the right bar showing the results of the system treated with RNase (RNase+).

[0045] As shown in FIG. 2, in system a, since miR-340 mimic was not added, amplification was not confirmed in either RNase- or RNase+. In system e, the mixture before ultracentrifugation contained free miR-340 mimic, but since the vesicle fraction was not added, the residue after ultracentrifugation did not contain miR-340 mimic, and amplification was not confirmed. In system d, since ultracentrifugation was not performed, free miR-340 mimic was contained in RNase- and amplification was confirmed, but since decomposition of free miR-340 mimic occurred by RNase, amplification was not confirmed in RNase+. In contrast, in systems b and c, since the vesicle fraction was added to cause the vesicle and the miR-340 mimic to coexist, amplification of miR-340 mimic was confirmed in both RNase- and RNase+. In other words, it can be said that the formation of a complex between the vesicle and the miR-340 mimic allowed decomposition by RNase to be avoided. Furthermore, since system c showed similar behavior to system b, it was found that a complex can be formed simply by allowing the vesicles and the miR-340 mimic to coexist without using, for example, a heat shock method.

[0046] (3) Confirmation of intracellular uptake 50 pmol of FITC-labeled miR-340 mimic was mixed with 1 mL of the vesicle fraction and left to stand at 4°C for 1 hour. This mixture was ultracentrifuged to collect the precipitate fraction and suspended in 50 μL of PBS (pH 7.2). This suspension was further diluted 1 / 10 with the PBS to prepare a dilution solution. Meanwhile, cervical cancer-derived cells SiHa were cultured in DMEM + 10% fetal bovine serum FBS medium, and 5 μL of the dilution solution was added to 500 μL of the culture solution and incubated in a CO2 incubator at 37°C for 24 hours. After culturing, the cells were observed under a fluorescent microscope. The cell nuclei were stained with DAPI. As a comparative example, the vesicle fraction alone or the labeled miR-340 mimic alone was used to culture and observe in the same manner. These results are shown in Figure 3.

[0047] FIG. 3 is an enlarged fluorescence micrograph, and the white line indicates the outline of one cell. A is the result of using only vesicles, B is the result of using vesicles and labeled miR-340 mimic, and C is the result of using only labeled miR-340 mimic. In FIG. 3, A shows DAPI fluorescence indicating the cell nucleus in the center of the cell, but FITC fluorescence was not confirmed within the cell because labeled miR-340 mimic was not added. C shows FITC fluorescence due to the addition of labeled miR-340 mimic, but the fluorescence was sparse because it was not introduced by vesicles. In contrast, B shows vesicle-shaped FITC fluorescence within the cell. This shows that labeled miR-340 mimic was taken up into the cell in a state of forming a complex with vesicles.

[0048] (4) In vitro target function: SiHa 50 pmol of the miR-340 mimic was mixed with 1 mL of the vesicle fraction and left to stand at 4°C for 1 hour. This mixture was ultracentrifuged to collect the precipitate fraction and suspended in 50 μL of PBS (pH 7.2). This suspension was further diluted 1 / 10 with the PBS to prepare a dilution solution. Meanwhile, cervical cancer-derived cells SiHa were cultured in DMEM + 10% FBS medium, and 5 μL of the dilution solution was added to 500 μL of the culture solution and incubated in a CO2 incubator at 37°C for 24 hours. After the culture, the cells were washed with PBS, RNA was extracted from the cells, and miR-340 mimic was measured by qRT-PCR. In addition, the expression of mRNA of MMP2, which is the target of miR-340 mimic, was also measured.

[0049] For comparison, similar analyses were performed on a system in which the miR-340 mimic was not added and only the vesicle fraction was used, a system in which 50 pmol of a nucleic acid that does not have the ability to inhibit expression (nega-miR, Thermo Fisher Scientific) was used instead of the miR-340 mimic, and a system in which the miR-340 mimic was not added and only the miR-340 mimic was used.

[0050] These results are shown in FIG. 4. FIG. 4 is a graph showing the relative expression levels of MMP2, and the Y axis is the value (relative value) of the expression level of MMP2 normalized by the expression level of beta-actin, a housekeeping gene. In FIG. 4, Acerola MV means the vesicle fraction (hereinafter, the same applies to other figures). As in the result of (3) above, the miR-340 mimic was detected from cells only in the system using the complex of the vesicles and the miR-340 mimic (not shown). As shown in FIG. 4, the expression of MMP2, which is the target of the miR-340 mimic, was confirmed only in the system using the complex of the vesicles and the miR-340 mimic (Acelora MV+miR-340 mimic). From these results, it can be seen that the miR-340 mimic was taken up into cells by forming a complex with the vesicles, and exerted the function of suppressing the expression of the target.

[0051] (5) Function on target in vitro: NHDF 50 pmol of a nucleic acid reagent miR-146a mimic (trade name Ambion (trademark) miR-146a mimic, Thermo Fisher Scientific) targeting NF-κB was mixed with 1 mL of the vesicle fraction and allowed to stand at 4°C for 1 hour. This mixture was ultracentrifuged to collect a precipitate fraction containing a complex of the miR-146a mimic and the vesicle, and suspended in 50 μL of PBS (pH 7.2). This suspension was further diluted 1 / 10 with the PBS to prepare a dilution solution. Meanwhile, human normal skin fibroblasts NHDF were cultured in DMEM + 10% FBS medium in the same manner as in (4) above, and 5 μL of the dilution solution was added to 500 μL of the culture solution, followed by incubation in a CO2 incubator at 37°C for 24 hours. After the culture, the cells were washed with PBS, RNA was extracted from the cells, and miR-146a mimic was measured by qRT-PCR (ADENs+miR-146a mimic). In addition, the expression of NF-κB mRNA, which is the target of miR-340 mimic, was also measured.

[0052] In addition, similar measurements were also performed on a system (ADENs) that used only the vesicle fraction without adding the miR-146a mimic, a system (ADENs+nega-miR) that used a nucleic acid that does not have the ability to inhibit expression (nega-miR, Thermo Fisher Scientific) instead of the miR-146a mimic, and a system (miR-146a mimic) that did not add the vesicle fraction.

[0053] These results are shown in FIG. 5. FIG. 5 is a graph showing the relative expression levels of NF-κB, and the Y axis is the value (relative value) of the expression level of NF-κB normalized with the expression level of beta-actin, a housekeeping gene. As in the results of SiHa in (4) above, the miR-146a mimic was detected from cells only in the system using the complex of the vesicles and the miR-146a mimic (not shown). As shown in FIG. 5, the expression of NF-κB, which is the target of the miR-146a mimic, was confirmed only in the system using the complex of the vesicles and the miR-146a mimic (ADENs+miR-146a mimic). These results show that the miR-146a mimic was taken up into cells by forming a complex with the vesicles, and exerted the function of suppressing the expression of the target. Furthermore, from the results of (4) and (5) above, it was confirmed that the vesicles can form a complex with a nucleic acid reagent and introduce the nucleic acid reagent into cells, regardless of the type of nucleic acid reagent or the type of cell.

[0054] Example 2 The vesicle fraction of Example 1 was used as the acerola-derived vesicles, and the function of the vesicles as a nucleic acid carrier was confirmed. Unless otherwise specified, the same conditions as those of Example 1 were used.

[0055] (1) 1 mL of the vesicle fraction was mixed with 200 pmol of the nucleic acid reagent (miR-340 mimic), calcium chloride was added, and the mixture was left on ice for 30 minutes, followed by a heat shock method. The mixture was then ultracentrifuged (100,000×g, 49,000 rpm, 70 minutes, 4°C), RNA was extracted from the resulting precipitate fraction, and miR-340 mimic was measured by qRT-PCR. In addition to this system (calcium chloride (+) / ice cooling (+) / heat shock (+)), measurements were also performed on the following systems with different conditions. Calcium chloride (+) / ice cooling (+) / heat shock (+) Calcium chloride (-) / ice cooling (+) / heat shock (+) Calcium chloride (-) / ice cooling (+) / heat shock (-)

[0056] These results are shown in FIG. 6. FIG. 6 is a graph showing the amount of amplification (detection amount) of miR-340 mimic in each system. The Y axis is the relative value of the amount of amplification of miR-340 mimic. Specifically, the amount of amplification of miR-340 mimic in each system was normalized in the same manner as in Example 1, and the normalized value of the calcium chloride (+) / ice-cooling (+) / heat shock (+) system was set to 1, and the relative value was expressed. As shown in FIG. 6, even when heat shock treatment was performed without adding calcium chloride, amplification of miR-340 mimic was observed for RNA recovered from the precipitate fraction after ultracentrifugation, and further, when heat shock treatment was not performed without adding calcium chloride, a higher relative value was obtained. From this, it was found that the formation of a complex between miR-340 mimic and vesicles can be performed simply by allowing both to coexist.

[0057] (2) 200 pmol of the nucleic acid reagent miR-340 mimic was mixed with 1 mL of the vesicle fraction, and the mixture was left on ice for 30 minutes (ice-cooled), then ultracentrifuged (UC, 100,000×g, 49,000 rpm, 70 minutes, 4° C.) to recover the precipitate fraction. RNA was extracted from the precipitate fraction, and miR-340 mimic was measured by qRT-PCR. Note that calcium chloride was not added, and heat shock was not treated. In addition to this system (vesicles (+) / miRNA mimic (+) / ice-cooled (+) / UC (+)), the following systems with changed conditions were also measured. Vesicles (-) used 1 mL of PBS instead of the vesicle fraction, miRNA mimic (-) used only the vesicle fraction without adding the miR-340 mimic, and UC (-) was a system in which RNA was extracted after ice-cooling without ultracentrifugation. Vesicles (+) / miRNA mimic (+) / ice-cold (+) / UC (+) Vesicles (+) / miRNA mimic (+) / ice-cold (+) / UC (-) Vesicles (+) / miRNA mimic (-) / ice-cold (+) / UC (+) Vesicles (+) / miRNA mimic (-) / ice-cold (+) / UC (-) Vesicles (-) / miRNA mimic (+) / ice-cold (+) / UC (+) Vesicles (-) / miRNA mimic (+) / ice-cold (+) / UC (-)

[0058] These results are shown in FIG. 7. FIG. 7 is a graph showing the amount of amplification (detection amount) of miR-340 mimic in each system. The Y axis is the relative value of the amount of amplification of miR-340 mimic. Specifically, for each system, the amount of amplification of miR-340 mimic was normalized in the same manner as in Example 1, and the normalized value of the vesicle (-) / miRNA mimic (+) / ice-cooled (+) / UC (-) system was set to 1, and the relative value was expressed. In FIG. 7, ADENs means the vesicle fraction of Example 1, that is, acerola-derived exosome-like vesicles (acerola derived exosome like nanoperticles) (hereinafter, the same applies to other figures). As shown in FIG. 7, in the system to which miRNA mimic was not added (vesicle (+) / miRNA mimic (-)), no amplification of miR-340 mimic was observed regardless of the presence or absence of ultracentrifugation (UC (+) or (-)). In the system without addition of the vesicle fraction (vesicle (-) / miRNA mimic (+)), amplification of miR-340 mimic was observed in the case of untreated ultracentrifugation (UC (-)), but amplification of miR-340 mimic was not observed in the case of treated ultracentrifugation (UC (+)). On the other hand, in the system with addition of the vesicle fraction and miRNA mimic (vesicle (+) / miRNA mimic (+)), amplification of miR-340 mimic was confirmed even after ultracentrifugation (UC (+)), although it was slightly decreased compared to the case of untreated ultracentrifugation (UC (-)). Since miRNA mimic cannot be precipitated by itself under the ultracentrifugation conditions, the fact that amplification of miRNA mimic was observed in the precipitate fraction obtained by ultracentrifugation due to coexistence with the vesicle fraction means that miRNA mimic forms a complex with vesicles.

[0059] (3) For calcium chloride (-) / ice cooling (+) / heat shock (-) in (1), measurements were performed in the same manner, but with different ice-cooling times. In addition, calcium chloride (-) / ice cooling (-) / heat shock (-) was performed in the same manner, but with different ice-cooling times at room temperature (25°C).

[0060] These results are shown in FIG. 8. FIG. 8 is a graph showing the amount of amplification (detection amount) of miR-340 mimic in each system. The Y axis is the relative value of the amount of amplification of miR-340 mimic. Specifically, the amount of amplification of miR-340 mimic in each system was normalized in the same manner as in Example 1, and the relative value was expressed when the normalized value of the system cooled on ice (+) 60 minutes was set to 1. As shown in FIG. 8, the amplification of miR-340 mimic was observed in the nucleic acid reagent and the vesicle fraction both when left on ice and at room temperature. Since the amount of amplification was slightly higher when left on ice than when left at room temperature, it is considered that, for example, the decomposition of the nucleic acid reagent is further protected by leaving on ice until the complex formation between the nucleic acid reagent and the vesicle of the vesicle fraction.

[0061] (4) For the calcium chloride (-) / ice-cooling (+) / heat shock (-) system described in (1), measurements were performed in the same manner, except that the amount of the vesicle fraction added in (1) was added at 1 / 2, 1 / 10, or 1 / 50 of the relative value of 1.

[0062] These results are shown in Figure 9. Figure 9 is a graph showing the amount of amplification (detection amount) of miR-340 mimic in each system. The Y axis is the relative value of the amount of amplification of miR-340 mimic. Specifically, for each system, the amount of amplification of miR-340 mimic was normalized in the same manner as in Example 1, and the normalized value of the system in which the relative value of the amount of the vesicle fraction added was 1 was set to 1, and the relative value was expressed as 1. As shown in Figure 9, the amount of amplification increased in a concentration-dependent manner with respect to the amount of the vesicle fraction added.

[0063] (5) In this example, the vesicle fraction (2.2 × 10 850 pmol of nucleic acid reagent (miR-340 mimic) was mixed with 50 μL of vesicles containing 100,000×g of 100 μL of 100 μl ...

[0064] The control contains the entire miR-340 mimic. On the other hand, in the example, the free miR-340 mimic is removed by ultracentrifugation, so the amount of the miR-340 mimic that forms the complex is amplified. Therefore, under the conditions of this example, vesicles of 1.1 × 10 7 It was found that 30 pmol of miR-340 mimic could be used as a complex using particles.

[0065] Example 3 The effect of acerola-derived vesicles on the resistance of nucleic acid reagents was confirmed. Unless otherwise specified, the conditions were the same as those in Example 1 or Example 2.

[0066] In Example 3, the nucleic acid reagent miR-340 mimic and the vesicle fraction were mixed in the same manner as in Example 2(2), and the mixture was left to stand on ice for 30 minutes, and then the mixture was ultracentrifuged to recover a precipitated fraction without carrying out the calcium chloride treatment and the heat shock treatment. Various damaging reagents (RNase, HCl, or NaOH) that damage nucleic acids were added to the precipitated fraction, and the precipitated fraction was treated under predetermined conditions, after which RNA was extracted and miR-340 mimic was measured by qRT-PCR. As a control in the example, RNA was extracted without adding the various damaging reagents, and the measurement was performed in the same manner.

[0067] The reagents used were RNase, HCl, and NaOH. The RNase was added to the precipitate fraction at 5 μg / mL, and the precipitate fraction was treated at 37° C. for 1 hour, after which RNA was extracted. The HCl was added to the precipitate fraction at 1×10 -2 The precipitate fraction was treated at 37° C. for 1 hour, and then RNA was extracted. -2 After incubation at 37°C for 1 hour, RNA was extracted.

[0068] In addition, in the comparative example, the nucleic acid reagent miR-340 mimic was treated under a predetermined condition by adding the various reagents (RNase, HCl, or NaOH) without adding the vesicle fraction, and then RNA was extracted and miR-340 mimic was measured by qRT-PCR. The various reagents were added to the nucleic acid reagent in the same amount as those added to the precipitate fraction in the examples, and the treatment conditions were the same. In the control of the comparative example, RNA was extracted without adding the various damage reagents, and the measurement was performed in the same manner.

[0069] These results are shown in Figure 10. Figure 10(A) is a graph showing the amount of amplification (detection amount) of miR-340 mimic in the example, and Figure 10(B) is a graph showing the amount of amplification (detection amount) of miR-340 mimic in the comparative example. Each Y axis is the relative value of the amount of amplification of miR-340 mimic, and each amount of amplification of miR-340 mimic was normalized in the same manner as in Example 1, and expressed as a relative value when the normalized value of each control was set to 1. As shown in Figure 10(B), in the case of the comparative example using miR-340 mimic alone, the amount of amplification of miR-340 mimic was significantly reduced when treated with any of the reagents (RNase, HCl, or NaOH). On the other hand, as shown in Figure 10 (A), in the embodiment, by allowing the miR-340 mimic to coexist with the vesicle fraction, the amplification amount of the miR-340 mimic was not significantly decreased as in the comparative example, and the amplification amount was maintained at more than half that of the control, regardless of whether the treatment was performed with any reagent. From this result, it was found that the addition of the vesicle fraction caused the vesicle and the miR-340 mimic to form a complex, thereby suppressing the degradation of the miR-340 mimic caused by various damage reagents.

[0070] Example 4 50 pmol of luc siRNA (trade name: Gene Design, anti-luc siRNA) targeting the luciferase gene was mixed with 1 mL of the vesicle fraction of Example 1, and left to stand at 4°C for 1 hour. This mixture was ultracentrifuged to collect the precipitate fraction, which was then suspended in 50 μL of PBS (pH 7.2). Meanwhile, luc-expressing cells (3LL-luc, obtained from the JCRB cell bank and transfected with the luciferase gene) were cultured in a well plate in DMEM + 10% FBS medium, and 5 μL of the suspension was added to 500 μL of the culture solution, and incubated in a CO2 incubator at 37°C for 24 hours. The luciferase activity of the cells after the culture was measured. The luciferase activity of the cells was measured as follows. 100 μL of Bio-Glo reagent (trade name: Promega) was added to the culture solution after the culture, and the solution was left to stand at room temperature in the dark for 15 minutes. Luciferase activity was then measured using a luminometer (Tecan). In addition, the number of cells was measured using CellTiter-Glo 2.0 assay (Promega) for cells cultured under the same conditions as above in another well plate. In addition, luciferase activity and cell number were measured in the same manner for the luc siRNA(-) / vesicle(+) system and the luc siRNA(+) / vesicle(-) system as controls.

[0071] These results are shown in Figure 11. Figure 11 is a graph showing luciferase activity, and the Y axis shows luciferase activity normalized by cell number. In the figure, * indicates P<0.05. As shown in Figure 11, when the vesicle fraction and the siRNA were used in combination, luciferase activity was significantly reduced.

[0072] Example 5 The in vivo DDS effect of acerola-derived vesicles was confirmed.

[0073] (1) Vesicle administration The vesicle fraction of Example 1 (2.2×10 82 mL of the vesicle fraction (2 mL of 100000×g particles / mL) was treated with PKH26, a fluorescent cell membrane staining dye, to fluorescently label the vesicles contained in the fraction. The vesicle fraction treated with PKH26 was subjected to ultracentrifugation (conditions: 100,000×g, 49,000 rpm, 70 min, 4°C), and the precipitate fraction containing the fluorescently labeled vesicles was collected, and the entire amount was suspended in 200 μL of PBS. The entire amount of the suspension of the fluorescently labeled vesicles was orally administered to multiple wild-type mice (female, 8 weeks old, C57 / BL) using a stomach tube. Then, the fluorescent signal was detected for each mouse over time (1 hour, 3 hours, 6 hours) using an in vivo fluorescence detection device (product name IVIS, Sumitomo Pharma International Co., Ltd.).

[0074] FIG. 12 shows a schematic diagram of imaging showing the fluorescent signal in each organ of the mouse, and FIG. 12 shows the site where a particularly prominent fluorescent signal was shown in the fluorescent signal imaging image. In FIG. 12, an asterisk means that a fluorescent signal was confirmed, its size indicates the relative size of the fluorescent signal, and its number indicates the distribution width of the fluorescent signal in each organ. FIG. 12 shows the results one hour after administration, and the shaded areas are the areas that showed fluorescence. As shown in FIG. 12, a fluorescent signal was confirmed in each area (brain, liver, stomach, intestinal tract, bladder), and it was found that the labeled vesicles were delivered to each of the above areas within one hour of administration. As time passed, the fluorescent signal attenuated, but even six hours after administration, a fluorescent signal was confirmed locally in the rectum.

[0075] (2) Vesicle-based delivery of nucleic acid reagents 200 pmol of the nucleic acid reagent Arabidopsis thaliana miRNA (ath-miR-159) was mixed with 2 mL of the vesicle fraction, and the mixture was left to stand on ice for 30 minutes (ice-cooled), and the entire amount was orally administered to mice in the same manner as in (1) above. One hour after oral administration, each organ was removed from the mouse, RNA was extracted, and ath-miR-159 was detected in each organ by qRT-PCR. In addition, the same detection was performed on mice administered only the ath-miR-159 as a control.

[0076] These results are shown in FIG. 13. FIG. 13 is a graph showing the relative values ​​of the amplified amount (detected amount) of ath-miR-159 in each organ, and the Y axis is the value (relative value) obtained by normalizing the amplified amount of ath-miR-159 with the amplified amount (detected amount) of RNU6B, which is an endogenous control small RNA. As shown in FIG. 13, in the mice administered with only ath-miR-159, ath-miR-159 was below the detection limit in all organs and could not be detected (undetecet, UD). On the other hand, in the mice administered with the complex, the expression of ath-miR159 was similarly confirmed in the organs (liver, intestinal tract such as small intestine) in which a strong fluorescent signal was confirmed in (1) above. In addition, the ath-miR159 was also confirmed in the kidney and spleen.

[0077] (3) Expression of the function of the delivered nucleic acid reagent Since it was confirmed in (2) above that the vesicles can deliver nucleic acid reagents in vivo, it was confirmed whether the delivered nucleic acid reagents function at the delivered site.

[0078] The nucleic acid reagent was mixed with the vesicle fraction in the same manner as in (2) above, except that the same luc siRNA as in Example 4 was used as the nucleic acid reagent, and the mixture was ice-cooled for 30 minutes, and the entire amount was orally administered to mice. The mice used were luciferase transgenic mice (luc-Tg / C57BL / 6J, 12 weeks old). One hour after administration, the luciferase activity in each organ of each mouse after dissection was measured using a detection device (product name IVIS) in the same manner as in (1) above (ADENs+luc siRNA). As a control, PBS alone was orally administered, and luciferase activity was measured in the same manner (Control).

[0079] These results are shown in Figure 14. Figure 14(A) is a graph showing the luminance (Flux) of the entire mouse individual before dissection, and Figure 14(B) is a graph showing the total luminance of the excised organs (brain, lungs, liver, kidneys, spleen, intestines, and ovarian region including bladder). In each graph, the Y axis represents luminance (Flux, unit x 10 8 As shown in Figures 14(A) and (B), the brightness indicating luciferase activity was significantly reduced in the mice administered with the complex compared to the control. In addition, (B) is the total brightness in the organs in which the delivery of the nucleic acid reagent was confirmed in (2). Therefore, for the result of administration of the complex (ADENs+luc siRNA), the brightness of the individual mouse in (A) was compared with the total brightness of the organs in (B), and a significant decrease in the brightness compared to each control was confirmed in (B). From this result, it was found that the nucleic acid was delivered to each organ by forming the complex, and the expression of luciferase was suppressed.

[0080] Example 6 Vesicles from lemon and grey fruit were isolated.

[0081] Using the same method as in Example 1, vesicle fractions were prepared from juice squeezed from ripe lemons and juice squeezed from ripe grapefruits, and the particle size distribution of the vesicles contained in the vesicle fractions was confirmed. The vesicle concentration of the lemon-derived vesicle fraction was 1.84 × 10 11 The mean particle size was 113.7 nm, the mode was 79.1 nm, and the SD was 66.8 nm. The vesicle concentration of the grapefruit-derived vesicle fraction was 7.37 × 10 12 The mean particle size was 95.7 nm, the mode was 61.9 nm, and the SD was 30.5 nm.

[0082] The effect of the lemon-derived vesicles or the grapefruit-derived vesicles on the resistance of nucleic acid reagents was confirmed. Specifically, the nucleic acid reagent miR-340 mimic was measured in the same manner as in Example 3, except that the lemon-derived vesicle fraction and the grapefruit-derived vesicle fraction were used instead of the acerola-derived vesicle fraction. The control in this example was similar to the control in Example 3, except that no damage reagents were added.

[0083] As a comparative example for the examples using the lemon-derived vesicles or the grapefruit-derived vesicles, the comparative example for the example 3 (see FIG. 10(B)) was used.

[0084] These results are shown in Figure 15. Figure 15(A) is a graph showing the amount of amplification (detection amount) of miR-340 mimic in an example using the lemon-derived vesicle fraction, and Figure 15(B) is a graph showing the amount of amplification (detection amount) of miR-340 mimic in an example using the grapefruit-derived vesicle fraction. The Y axis of each graph is the relative value of the amount of amplification of miR-340 mimic, and the amount of amplification of miR-340 mimic was normalized in the same manner as in Example 1, and the normalized value of each control was set to 1, and the values ​​were expressed as relative values.

[0085] As shown in FIG. 10(B) above, in the case of the comparative example using only the miR-340 mimic, the amount of amplification of the miR-340 mimic was significantly reduced when treated with any of the reagents (RNase, HCl, or NaOH). On the other hand, as shown in FIG. 15(A), in the example, by allowing the miR-340 mimic to coexist with the lemon-derived vesicle fraction, the amount of amplification of the miR-340 mimic was not significantly reduced as in the comparative example, and the amount of amplification was maintained at more than half that of the control, regardless of the reagent used. Also, as shown in FIG. 15(B), the example using the grapefruit-derived vesicle fraction was similar. From these results, it was found that the addition of the vesicle fraction caused the vesicles and the miR-340 mimic to form a complex, thereby suppressing the decomposition of the miR-340 mimic caused by various damage reagents.

[0086] Although the present invention has been described above with reference to the embodiment, the present invention is not limited to the above embodiment. Various modifications that can be understood by those skilled in the art can be made to the configuration and details of the present invention within the scope of the present invention.

[0087] This application claims priority based on Japanese Patent Application No. 2019-126172, filed on July 5, 2019, the disclosure of which is incorporated herein in its entirety. [Industrial Applicability]

[0088] According to the nucleic acid carrier of the present invention, for example, a nucleic acid can be easily retained and the retained nucleic acid can be introduced into a cell. Therefore, the present invention can be said to be very useful in the medical field, for example, in gene therapy.

Claims

1. The invention comprises vesicles isolated from the fruit of a plant, A nucleic acid carrier, characterized in that the plant is an acerola species (Malpighia sp.) plant.

2. 2. The nucleic acid carrier according to claim 1, wherein the vesicles have an average particle size of 30 to 400 nm.

3. The nucleic acid carrier according to claim 1 or 2, wherein the nucleic acid is a nucleic acid reagent for expression inhibition.

4. Further comprising the nucleic acid, The nucleic acid carrier according to claim 1 , wherein the nucleic acid and the vesicle form a complex.

5. A nucleic acid carrier according to any one of claims 1 to 3, and a nucleic acid, A delivery-type nucleic acid reagent, characterized in that the nucleic acid carrier and the nucleic acid form a complex.

6. The delivery-type nucleic acid reagent according to claim 5 , wherein the nucleic acid is at least one selected from the group consisting of siRNA, antisense, shRNA, miRNA, and miRNA mimic.

7. A method for producing a delivery-type nucleic acid reagent, comprising a step of forming a complex between the nucleic acid carrier and the nucleic acid by causing the nucleic acid carrier described in any one of claims 1 to 3 and the nucleic acid to coexist in a solvent.

8. The method according to claim 7 , further comprising the step of mixing the nucleic acid carrier and the nucleic acid in the solvent and incubating the mixture.

9. The ratio of the nucleic acid carrier to 1 pmol of the nucleic acid is 5×10 4 ~8×10 4 The method according to claim 7 or 8, wherein the particles are particles.

10. A step of forming a complex between the nucleic acid carrier according to any one of claims 1 to 4 and a nucleic acid; administering the complex; A method for administering a nucleic acid, wherein the administration is in vitro or to a non-human animal.

11. The administration method described in claim 10, wherein in the step of forming the complex, the nucleic acid carrier and the nucleic acid are allowed to coexist to form a complex between the nucleic acid carrier and the nucleic acid.

Citation Information

Patent Citations

  • Edible plant-derived microvesicle compositions for diagnosis and treatment of disease

    US20140308212A1

  • EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER

    US20180362974A1

  • EDIBLE PLANT-DERIVED MICROVESICLE COMPOSITIONS FOR DELIVERY OF miRNA AND METHODS FOR TREATMENT OF CANCER

    WO2017004526A1